---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-010666"
form_type: "8-K"
ticker: "ZOMDF"
cik: "0001684144"
company_name: "Zomedica Corp."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:22:17.171965+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "medium"
source: SEC EDGAR
---

# Zomedica reports record FY2023 revenue $25.2M (+33% YoY); net loss $34.5M; guides FY2024 $31-35M

## Summary
- Q4 2023 revenue $7.3M (+19% YoY); FY2023 revenue $25.2M (+33% YoY), driven by Diagnostics (+252%) and Therapeutic Devices (+28%).
- Gross margin 69% for FY2023; consumable revenue $16.4M (+41% YoY), 65% of total revenue.
- Net loss $34.5M ($0.035/share) vs $17.0M in FY2022; Adjusted Non-GAAP EBITDA loss $12.8M.
- Cash and securities $100.5M at Dec 31, 2023; reiterated FY2024 revenue guidance $31-35M.
- Acquisitions of SMP (VetGuardian) and Qorvo Biotechnologies in 2023; launched TRUVIEW and new assays.

## SEC filing metadata
- accession: 0001654954-24-010666
- form_type: 8-K
- ticker: ZOMDF
- cik: 0001684144
- company_name: Zomedica Corp.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1684144/000165495424010666/0001654954-24-010666-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1684144/000165495424010666/zom_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-010666
- JSON: https://secwatch.observer/filing/0001654954-24-010666.json
- Plain text: https://secwatch.observer/filing/0001654954-24-010666.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.